Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Harbinger Health launches for cancer detection, led by former FDA head

by Ryan Cross
December 17, 2021 | A version of this story appeared in Volume 99, Issue 45

 

Flagship Pioneering, the life sciences investment firm that helped found Moderna, has launched its latest company, Harbinger Health, with $50 million of committed capital. Flagship founded Harbinger quietly in 2018 to develop blood-based tests for early cancer detection. Harbinger says the tests are based on advances in machine learning and the biology of early cancer. Stephen Hahn, a former US Food and Drug Administration commissioner, will be the start-up’s CEO.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.